Advertisement
MCP
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/mcp.M400124-MCP200 on October 8, 2004.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
M400124-MCP200v1
3/12/1181    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Glossary
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wissing, J.
Right arrow Articles by Daub, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wissing, J.
Right arrow Articles by Daub, H.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Molecular & Cellular Proteomics 3:1181-1193, 2004.
© 2004 by The American Society for Biochemistry and Molecular Biology, Inc.

Research

Chemical Proteomic Analysis Reveals Alternative Modes of Action for Pyrido[2,3-d]pyrimidine Kinase Inhibitors*

Josef Wissing, Klaus Godl, Dirk Brehmer, Stephanie Blencke, Martina Weber, Peter Habenberger, Matthias Stein-Gerlach, Andrea Missio, Matt Cotten, Stefan Müller and Henrik Daub{ddagger}

From Axxima Pharmaceuticals AG, 81377 München, Germany

Small molecule inhibitors belonging to the pyrido[2,3-d]pyrimidine class of compounds were developed as antagonists of protein tyrosine kinases implicated in cancer progression. Derivatives from this compound class are effective against most of the imatinib mesylate-resistant BCR-ABL mutants isolated from advanced chronic myeloid leukemia patients. Here, we established an efficient proteomics method employing an immobilized pyrido[2,3-d]pyrimidine ligand as an affinity probe and identified more than 30 human protein kinases affected by this class of compounds. Remarkably, in vitro kinase assays revealed that the serine/threonine kinases Rip-like interacting caspase-like apoptosis-regulatory protein kinase (RICK) and p38{alpha} were among the most potently inhibited kinase targets. Thus, pyrido[2,3-d]pyrimidines did not discriminate between tyrosine and serine/threonine kinases. Instead, we found that these inhibitors are quite selective for protein kinases possessing a conserved small amino acid residue such as threonine at a critical site of the ATP binding pocket. We further demonstrated inhibition of both p38 and RICK kinase activities in intact cells upon pyrido[2,3-d]pyrimidine inhibitor treatment. Moreover, the established functions of these two kinases as signal transducers of inflammatory responses could be correlated with a potent in vivo inhibition of cytokine production by a pyrido[2,3-d]pyrimidine compound. Thus, our data demonstrate the utility of proteomic methods employing immobilized kinase inhibitors for identifying new targets linked to previously unrecognized therapeutic applications.

{ddagger} To whom correspondence should be addressed: Axxima Pharmaceuticals AG, Max-Lebsche-Platz 32, 81377 München, Germany. Tel.: 49-89-550-65-356; Fax: 49-89-550-65-461; E-mail: henrik.daub{at}axxima.com


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Mol. Cell. ProteomicsHome page
T. Reinl, M. Nimtz, C. Hundertmark, T. Johl, G. Keri, J. Wehland, H. Daub, and L. Jansch
Quantitative Phosphokinome Analysis of the Met Pathway Activated by the Invasin Internalin B from Listeria monocytogenes
Mol. Cell. Proteomics, December 1, 2009; 8(12): 2778 - 2795.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
F. S. Oppermann, F. Gnad, J. V. Olsen, R. Hornberger, Z. Greff, G. Keri, M. Mann, and H. Daub
Large-scale Proteomics Analysis of the Human Kinome
Mol. Cell. Proteomics, July 1, 2009; 8(7): 1751 - 1764.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
N. Vajpai, A. Strauss, G. Fendrich, S. W. Cowan-Jacob, P. W. Manley, S. Grzesiek, and W. Jahnke
Solution Conformations and Dynamics of ABL Kinase-Inhibitor Complexes Determined by NMR Substantiate the Different Binding Modes of Imatinib/Nilotinib and Dasatinib
J. Biol. Chem., June 27, 2008; 283(26): 18292 - 18302.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
O. Hantschel, U. Rix, U. Schmidt, T. Burckstummer, M. Kneidinger, G. Schutze, J. Colinge, K. L. Bennett, W. Ellmeier, P. Valent, et al.
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib
PNAS, August 14, 2007; 104(33): 13283 - 13288.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
J. Wissing, L. Jansch, M. Nimtz, G. Dieterich, R. Hornberger, G. Keri, J. Wehland, and H. Daub
Proteomics Analysis of Protein Kinases by Target Class-selective Prefractionation and Tandem Mass Spectrometry
Mol. Cell. Proteomics, March 1, 2007; 6(3): 537 - 547.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Quintavalle, S. Sambucini, V. Summa, L. Orsatti, F. Talamo, R. De Francesco, and P. Neddermann
Hepatitis C Virus NS5A Is a Direct Substrate of Casein Kinase I-{alpha}, a Cellular Kinase Identified by Inhibitor Affinity Chromatography Using Specific NS5A Hyperphosphorylation Inhibitors
J. Biol. Chem., February 23, 2007; 282(8): 5536 - 5544.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
N. S. Azad, N. Rasool, C. M. Annunziata, L. Minasian, G. Whiteley, and E. C. Kohn
Proteomics in Clinical Trials and Practice: Present Uses and Future Promise
Mol. Cell. Proteomics, October 1, 2006; 5(10): 1819 - 1829.
[Abstract] [Full Text] [PDF]

Home page
 BioinformaticsHome page
G. M. Verkhivker
Imprint of evolutionary conservation and protein structure variation on the binding function of protein tyrosine kinases
Bioinformatics, August 1, 2006; 22(15): 1846 - 1854.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
L. Martin, V. Catherinot, and G. Labesse
kinDOCK: a tool for comparative docking of protein kinase ligands.
Nucleic Acids Res., July 1, 2006; 34(Web Server issue): W325 - W329.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Godl, O. J. Gruss, J. Eickhoff, J. Wissing, S. Blencke, M. Weber, H. Degen, D. Brehmer, L. Orfi, Z. Horvath, et al.
Proteomic Characterization of the Angiogenesis Inhibitor SU6668 Reveals Multiple Impacts on Cellular Kinase Signaling
Cancer Res., August 1, 2005; 65(15): 6919 - 6926.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Journal of Biological Chemistry 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2004 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement